Dissolution of xylitol from a food supplement administered with a novel slow-release pacifier: preliminary results

Taipale, Teemu; Pienihäkkinen, Kaisu; Alanen, Pentti; Jokela, Jorma; Söderling, Eva

doi:10.1007/bf03262581

Cited by 12 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, differences between different products, strains and also host individuals are obvious [Busscher et al, 1999;Petti et al, 2001;Haukioja et al, 2006;Krasse et al, 2006;Yli-Knuuttila et al, 2006]. Unfortunately, information on the oral colonisation of probiotic strains in children is not available, although probiotic bacteria are given even to newborns because of their broad beneficial health effects [Rautava, 2007;Taipale et al, 2007].…”

Section: Discussionmentioning

confidence: 99%

Acid Production from Sugars and Sugar Alcohols by Probiotic Lactobacilli and Bifidobacteria in vitro

2008

Self Cite

View full text Add to dashboard Cite

Some probiotic bacterial strains have been suggested to improve oral health. However, lactobacilli and bifidobacteria are associated with the progression of dental caries. The pH fall caused by 14 probiotic and dairy bacterial strains from glucose, lactose, sucrose, sorbitol and xylitol was followed. All strains used glucose, nine lactose and seven sucrose. Six of the lactobacilli caused a small decrease in pH with sorbitol and two with xylitol. None of the bifidobacteria fermented sugar alcohols. As all the strains could be considered acidogenic, more long-term clinical trials are needed before recommendations for oral health purposes can be made.

show abstract

Section: Discussionmentioning

confidence: 99%

Acid Production from Sugars and Sugar Alcohols by Probiotic Lactobacilli and Bifidobacteria in vitro

2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The delivery method was tested before the study began: both the BB-12-xylitol tablet and the control xylitol tablet dissolved from the pouch of the pacifier slowly and completely during 7-15 min of sucking [Taipale et al, 2007]. Thus, the probiotic tablet could be delivered in a controlled manner using the new pacifier.…”

Section: Discussionmentioning

confidence: 99%

“…The families were informed that they could receive tablets and pacifiers until the child was 24 months old. The pacifier contained a pouch into which the tablet was inserted [Taipale et al, 2007]. Until 6-8 months of age, the children received the tablet via a small pacifier, thereafter via a larger pacifier.…”

Section: Interventionsmentioning

confidence: 99%

“…Sorbitol is generally considered to be an inert polyol and is commonly used as a control in clinical xylitol studies [Mäkinen et al, 1995;Milgrom et al, 2009;Söderling, 2009]. We have shown earlier that the test tablet dissolved in a controlled way from the pouch of the pacifier, and that the administration method is feasible [Taipale et al, 2007]. We hypothesized that (1) the administration of BB-12 to young healthy children may reduce the colonization by MS, and (2) BB-12 would show poor colonization in the mouths of the children.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bifidobacteriumanimalis subsp. lactis BB-12 Administration in Early Childhood: A Randomized Clinical Trial of Effects on Oral Colonization by Mutans Streptococci and the Probiotic

Taipale¹,

Pienihäkkinen²,

Salminen

et al. 2012

Caries Res

Self Cite

View full text Add to dashboard Cite

A randomized clinical trial studied the effects of early ad-ministration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on oral colonization of (1) mutans streptococci (MS), and (2) BB-12. In this double-blind, placebo-controlled study, infants (n = 106) received probiotic bacteria (BB-12 group), xylitol (X group), or sorbitol (S group). Test tablets were administered twice a day (from the age of 1-2 months) with a novel slow-release pacifier or a spoon (daily dose of BB-12 10¹⁰ CFU, polyol 200-600 mg). Samples were collected from mucosa/teeth at the age of 8 months and 2 years for BB- 12 determination (qPCR) and plate culturing of MS (MSB, TYCSB), lactobacilli (Rogosa) and yeasts (Sabouraud). The MS levels of the mothers were determined (Dentocult SM Strip Mutans). The baseline characteristics of the three groups were similar. Mean duration of tablet delivery was 14.9 ± 6.7 months. In all groups, >90% of the mothers showed high MS counts (log CFU ≧5). MS colonization percentages of the children at the age of 2 years were rather low (BB-12 group: 6%; X group: 31%; S group: 10%; p < 0.05). The levels of lactobacilli and yeasts did not differ between the groups. BB-12 cell counts barely exceeding the detection limit were found in three of the oral samples of the 8-month-old children; however, the 2-year samples did not contain BB-12. The early administration of BB-12 did not result in permanent oral colonization of this probiotic or significantly affect MS colonization in the children.

show abstract

“…We have earlier introduced a controlled administration method for probiotic supplementation via a novel slow-release pacifier (15). We delivered to infants a probiotic tablet containing BB-12.…”

mentioning

confidence: 99%

Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood

Taipale¹,

Pienihäkkinen

Isolauri

et al. 2015

Pediatr Res

View full text Add to dashboard Cite

ArticlesBackground: Specific probiotic bacteria have proven to be effective in the prevention and treatment of infectious diseases in early life in at-risk populations. The impact of administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy children. Methods: In this double-blind, placebo-controlled study, 109 1-mo-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n = 55) or a placebo (n = 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 y with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications, and all signs and symptoms of acute infections were registered in diaries by parents and in questionnaires by trained professionals. results: The infants receiving BB-12 were reported to have experienced fewer respiratory tract infections (RTIs; 87 vs. 100%; risk ratio: 0.87; 95% confidence interval: 0.76, 1.00; P = 0.033) than the controls. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media, or fever. The baseline characteristics of the two groups were similar, as was the duration of breastfeeding. conclusion: Administration of BB-12 in early childhood may reduce RTIs.

show abstract

Dissolution of xylitol from a food supplement administered with a novel slow-release pacifier: preliminary results

Abstract: Xylitol released from the food supplement, delivered with the novel pacifier, may result in salivary xylitol concentrations high enough to inhibit mutans streptococci in vivo.

Cited by 12 publications

References 9 publications

Acid Production from Sugars and Sugar Alcohols by Probiotic Lactobacilli and Bifidobacteria in vitro

Acid Production from Sugars and Sugar Alcohols by Probiotic Lactobacilli and Bifidobacteria in vitro

<i>Bifidobacterium</i><i>animalis</i> subsp. <i>lactis</i> BB-12 Administration in Early Childhood: A Randomized Clinical Trial of Effects on Oral Colonization by Mutans Streptococci and the Probiotic

Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood

Contact Info

Product

Resources

About